Treatments for non-small-cell lung cancer [ID6234]
Discontinued
Reference number: GID-TA11289
Any companies with a medicine that meets the eligibility and selection criteria for technology appraisal guidance (see sections 4.1.4 and 6.2.1 of the manual) can request to
become a NSCLC pathway company stakeholder. Companies with medicines which are expected to get appropriate regulatory approval beyond 24 months are also eligible to request to become a pathway
stakeholder.
For more information please email TAteam6@nice.org.uk.